Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Sep;72(9):6988-96.
doi: 10.1128/JVI.72.9.6988-6996.1998.

Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage

Affiliations

Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage

D Cecilia et al. J Virol. 1998 Sep.

Abstract

Most strains of human immunodeficiency virus type 1 (HIV-1) which have only been carried in vitro in peripheral blood mononuclear cells (primary isolates) can be neutralized by antibodies, but their sensitivity to neutralization varies considerably. To study the parameters that contribute to the differential neutralization sensitivity of primary HIV-1 isolates, we developed a neutralization assay with a panel of genetically engineered cell lines (GHOST cells) that express CD4, one of eight chemokine receptors which function as HIV-1 coreceptors, and a Tat-dependent green fluorescent protein reporter cassette which permits the evaluation and quantitation of HIV-1 infection by flow cytometry. All 21 primary isolates from several clades could grow in the various GHOST cell lines, and their use of one or more coreceptors could easily be defined by flow cytometric analysis. Ten of these primary isolates, three that were CXCR4 (X4)-tropic, three that were CCR5 (R5)-tropic, and four that were dual- or polytropic were chosen for study of their sensitivity to neutralization by human monoclonal and polyclonal antibodies. Viruses from the X4-tropic category of viruses were first tested since they have generally been considered to be particularly neutralization sensitive. It was found that the X4-tropic virus group contained both neutralization-sensitive and neutralization-resistant viruses. Similar results were obtained with R5-tropic viruses and with dual- or polytropic viruses. Within each category of viruses, neutralization sensitivity and resistance could be observed. Therefore, sensitivity to neutralization appears to be the consequence of factors that influence the antibody-virus interaction and its sequelae rather than coreceptor usage. Neutralization of various viruses by the V3-specific monoclonal antibody, 447-52D, was shown to be dependent not only on the presence of the relevant epitope but also on its presentation. An epitope within the envelope of a particular virus is not sufficient to render a virus sensitive to neutralization by an antibody that recognizes that epitope. Moreover, conformation-dependent factors may overcome the need for absolute fidelity in the match between an antibody and its core epitope, permitting sufficient affinity between the viral envelope protein and the antibody to neutralize the virus. The studies indicate that the neutralization sensitivity of HIV-1 primary isolates is a consequence of the complex interaction between virus, antibody, and _target cell.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Twenty-one primary isolates were tested for their coreceptor preference in GHOST cells expressing CCR1, CCR2, CCR3, CCR5, CXCR4, BOB, or Bonzo. The virus isolates were either SI (A), NSI (B), or dual- or polytropic (C). One representative experiment of two or three is shown, with values being the mean of duplicate observations. The mean number of fluorescent cells observed in GHOST-CCR1 cells with all 21 viruses + 2 standard deviations was the cutoff value (horizontal line).
FIG. 2
FIG. 2
Syncytia seen in GHOST-C5 cells infected with NSI virus VI313 (A) or with dualtropic virus 89.6 (B). (C) Uninfected cells.
FIG. 3
FIG. 3
(A) Kinetics of infection of SF33 in GHOST-X4 (■) and GHOST-R5 (□) cells and of 92HT593 in GHOST-X4 (•) and GHOST-R5 (○) cells. (B and C) Effect of pretreatment with HIV immune serum pool 2 (▴) and normal serum (■) on the infection kinetics of SF33 in GHOST-X4 (B) and GHOST-R5 (C) cells. Sera were tested at a final dilution of 1:40.
FIG. 4
FIG. 4
Neutralization of SF2 by three immune sera (N, F, and FDA-2) in GHOST-X4 (bold lines) and GHOST-R5 (dashed lines) cells. Each serum dilution was tested in duplicate, and the percent neutralization was calculated by using the mean. The dose-response curves obtained are from one representative experiment of two or three carried out with each serum sample.
FIG. 5
FIG. 5
The 50% neutralizing titers shown on the y axis were determined for 10 primary isolates with seven antibody preparations. The X4-tropic viruses were tested on GHOST-X4 cells (A), the R5-tropic viruses were tested on GHOST-R5 cells (B), and the polytropic viruses were tested on GHOST-X4 (C) or GHOST-R5 (D) cells. Fivefold dilutions of the Ab preparations were tested for neutralization against a fixed dilution of virus. The stocks of the MAb preparations were adjusted to 1 mg/ml; thus, a titer of 1:1,000 is equivalent to 1 μg/ml. HIVIG-Ug was used at a starting concentration of 0.5 mg/ml; thus, an HIVIG-Ug titer of 1:1,000 corresponds to 0.5 μg/ml. Antibody preparations that did not neutralize an isolate at the lowest dilution tested (1:40) are shown graphically with an arbitrary titer of 1:15, which should be considered negative.

Similar articles

Cited by

References

    1. Arendrup M, Sonnerborg A, Svennerholm B, Akerblom L, Nielsen C, Clausen H, Olofsson S, Nielsen J O, Hansen J S. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol. 1993;74:855–863. - PubMed
    1. Armstrong S J, McInerney T L, McLain L, Wahren B, Hinkula J, Levi M, Dimmock N J. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J Gen Virol. 1996;77:2931–2941. - PubMed
    1. Auewarakul P, Louisirirotchanakul S, Sutthent R, Taechowisan T, Kanoksinsombat C, Wasi C. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env genetic subtype B and E viruses in Thailand. Viral Immunol. 1996;9:175–185. - PubMed
    1. Back N K, Smit L, Hogervorst E, van Wijk A C, Goudsmit J, Tersmette M. Development and evaluation of an HIV-1 transfection-neutralization assay. J Acquired Immune Defic Syndr. 1994;7:531–538. - PubMed
    1. Bandres J C, Wang Q F, O’Leary J, Baleaux F, Amara A, Hoxie J, Zolla-Pazner S, Gorny M K. Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J Virol. 1998;72:2500–2504. - PMC - PubMed

Publication types

  NODES
chat 2
twitter 2